title: Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature.
abstract: BACKGROUND
  The standard treatment for endometrial carcinoma is staging laparotomy with total abdominal hysterectomy and bilateral salpingo-oophorectomy. In an attempt to preserve childbearing potential, selected patients with endometrial carcinoma were treated with progestin alone as primary therapy.
  
  
  METHODS
  Patients were identified through searches of tumor registries and solicitation of consulting gynecologic oncologists at the affiliated institutions of the University of California-Los Angeles Center for the Health Sciences. Only those patients with a diagnosis of endometrial carcinoma treated with progestin alone as primary therapy were included in the study. Independent pathologic review was performed by a recognized expert gynecologic pathologist to exclude cases of endometrial hyperplasia. A MEDLINE search was conducted to identify reports of similarly treated patients.
  
  
  RESULTS
  Seven patients were treated with progestin alone for endometrial carcinoma at the study institution. Fourteen additional patients were identified through the literature search. Combining the data for all patients, 13 of 21 patients (62%) had an initial response to progestins. Three initial responders later developed recurrent disease, one of whom was found to have extrauterine disease at laparotomy. Eight of 21 patients (38%) did not respond to progestins and underwent more definitive treatment. None of these patients later developed recurrent disease. Six viable infants were delivered of three patients after therapy. Nineteen of 21 patients were alive without evidence of disease at last follow-up.
  
  
  CONCLUSIONS
  The results of this study show that premenopausal women with endometrial carcinoma may be treated successfully with progestin therapy alone as primary therapy to preserve childbearing potential.
authors.affiliation: Department of Obstetrics and Gynecology, University of California-Los Angeles School of Medicine 90024, USA.
authors.forename: Y B
authors.initials: YB
authors.lastname: Kim
authors.forename: C H
authors.initials: CH
authors.lastname: Holschneider
authors.forename: K
authors.initials: K
authors.lastname: Ghosh
authors.forename: R K
authors.initials: RK
authors.lastname: Nieberg
authors.forename: F J
authors.initials: FJ
authors.lastname: Montz
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019290:Megestrol Acetate / Q000627:therapeutic use*; D017697:Premenopause; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D019290:Megestrol Acetate